HIV/HBV合并感染者的HBeAg状态与免疫重建的关系

The Relationship Between HBeAg Status and Immune Reconstruction in the Patients of HIV/HBV Co-infections

目的了解人类免疫缺陷病毒(HIV)/乙型肝炎病毒(HBV)合并感染者的HBeAg状态与高效抗反转录病毒治疗(HAART)后患者免疫重建的关系。方法69例HIV/HBV合并感染者按HBeAg的状态分为HBeAg阳性组(26例)和HBeAg阴性组(43例);分别对两组患者治疗后1年、2年、3年的CD4^+T淋巴细胞的增长值进行比较。结果两组患者在接受HAART治疗3年后,外周血HIV RNA载量均低于检测下限(<20拷贝/mL)。两组患者基线CD4^+T淋巴细胞计数的比较差异无统计学意义。HBeAg阴性组合并感染者接受HAART治疗后1年、2年、3年的CD4^+T细胞计数的增长值均明显低于HBeAg阳性组合并感染者,差异具有统计学意义(P<0.05)。结论HBeAg的状态可能影响HIV/HBV合并感染者接受HAART治疗后的免疫重建。

Objective To investigate the relationship between the HBeAg status of HIV/ hepatitis B virus ( HBV) co-infected patients and immune reconstruction after highly active antiretroviral therapy ( HAART). Methods According to the status of HBeAg ,69 HIV/HBV co-infected patients were divided into the HBeAg positive (26 cases) and the HBeAg negative group (43 cases). The proliferation of CD4^+ T lymphocytes was compared between the two groups 1 to 3 years after HAART treatments. Results The proliferation of CD4^+ T lymphocytes in the HBeAg negative group were significantly lower than that in the HBeAg positive group in the first, second and third year after HAART treatment (P <0. 05 ). Conclusion The status of HBeAg may affect the immune reconstruction after HAART in patients with HIV/ HBV co-infections.